Bagust A - Search Results

1

Evaluating the performance of the Framingham risk equations in a population with diabetes.

McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, Currie CJ. McEwan P, et al. Among authors: bagust a. Diabet Med. 2004 Apr;21(4):318-23. doi: 10.1111/j.1464-5491.2004.01139.x. Diabet Med. 2004. PMID: 15049932

2

An economic model of the long-term health care burden of Type II diabetes.

Bagust A, Hopkinson PK, Maier W, Currie CJ. Bagust A, et al. Diabetologia. 2001 Dec;44(12):2140-55. doi: 10.1007/s001250100023. Diabetologia. 2001. PMID: 11793015

3

The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060.

Bagust A, Hopkinson PK, Maslove L, Currie CJ. Bagust A, et al. Diabet Med. 2002 Jul;19 Suppl 4:1-5. doi: 10.1046/j.1464-5491.19.s4.2.x. Diabet Med. 2002. PMID: 12121330

4

Guidelines for computer modeling of diabetes and its complications: response to American Diabetes Association Consensus Panel.

Bagust A, McEwan P. Bagust A, et al. Diabetes Care. 2005 Feb;28(2):500; author reply 500-1. doi: 10.2337/diacare.28.2.500. Diabetes Care. 2005. PMID: 15677831 No abstract available.

5

Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK.

Shearer A, Bagust A, Sanderson D, Heller S, Roberts S. Shearer A, et al. Among authors: bagust a. Diabet Med. 2004 May;21(5):460-7. doi: 10.1111/j.1464-5491.2004.01183.x. Diabet Med. 2004. PMID: 15089791

6

Deteriorating beta-cell function in type 2 diabetes: a long-term model.

Bagust A, Beale S. Bagust A, et al. QJM. 2003 Apr;96(4):281-8. doi: 10.1093/qjmed/hcg040. QJM. 2003. PMID: 12651972

7

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Beale S, Bagust A, Shearer AT, Martin A, Hulme L. Beale S, et al. Among authors: bagust a. Pharmacoeconomics. 2006;24 Suppl 1:21-34. doi: 10.2165/00019053-200624001-00003. Pharmacoeconomics. 2006. PMID: 16800160 Review.

8

Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.

Shearer AT, Bagust A, Liebl A, Schoeffski O, Goertz A. Shearer AT, et al. Among authors: bagust a. Pharmacoeconomics. 2006;24 Suppl 1:35-48. doi: 10.2165/00019053-200624001-00004. Pharmacoeconomics. 2006. PMID: 16800161 Review.

9

Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.

Bagust A, Beale S. Bagust A, et al. Health Econ. 2005 Mar;14(3):217-30. doi: 10.1002/hec.910. Health Econ. 2005. PMID: 15386666

10

A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.

Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M. Bagust A, et al. Pharmacoeconomics. 2006;24 Suppl 1:5-19. doi: 10.2165/00019053-200624001-00002. Pharmacoeconomics. 2006. PMID: 16800159 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters